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Abstract
Aims/hypothesis We investigated the molecular mechanism
by which the human glucagon-like peptide-1 analogue
liraglutide preserves pancreatic beta cells in diabetic db/db
mice.
Methods Male db/db and m/m mice aged 10 weeks
received liraglutide or vehicle for 2 days or 2 weeks. In
addition to morphological and biochemical analysis of
pancreatic islets, gene expression profiles in the islet core
area were investigated by laser capture microdissection and
real-time RT-PCR.
Results Liraglutide treatment for 2 weeks improved meta-
bolic variables and insulin sensitivity in db/db mice.
Liraglutide also increased glucose-stimulated insulin secre-
tion (GSIS) and islet insulin content in both mouse strains
and reduced triacylglycerol content in db/db mice. Expres-
sion of genes involved in cell differentiation and prolifer-
ation in both mouse strains was regulated by liraglutide,
which, in db/db mice, downregulated genes involved in
pro-apoptosis, endoplasmic reticulum (ER) stress and lipid
synthesis, and upregulated genes related to anti-apoptosis
and anti-oxidative stress. In the 2 day experiment, liraglu-
tide slightly improved metabolic variables in db/db mice,
but GSIS, insulin and triacylglycerol content were not
affected. In db/db mice, liraglutide increased gene expres-
sion associated with cell differentiation, proliferation and
anti-apoptosis, and suppressed gene expression involved in
pro-apoptosis; it had no effect on genes related to oxidative
stress or ER stress. Morphometric results for cell prolifer-
ation, cell apoptosis and oxidative stress in db/db mice
islets were consistent with the results of the gene expression
analysis.
Conclusions/interpretation Liraglutide increases beta cell
mass not only by directly regulating cell kinetics, but also
by suppressing oxidative and ER stress, secondary to
amelioration of glucolipotoxicity.
Keywords Apoptosis.Beta cell mass.Cellular
differentiation.Cellular proliferation.ER stress.
Glucagon-like peptide-1.Oxidative stress
Abbreviations
eIF2α Eukaryotic translation initiation factor 2 α
ER Endoplasmic reticulum
ERK Extracellular signal-regulated kinase
GLP-1 Glucagon-like peptide-1
GSIS Glucose-stimulated insulin secretion
HES1 Hairy and enhancer of split-1
4HNE 4-Hydroxy-2-noneal modified protein
MAPK Mitogen-activated protein kinase
PCNA Proliferative cell nuclear antigen
PI3K Phosphoinositide 3-kinase
Introduction
It is widely accepted that beta cell function progressively
deteriorates in individuals with type 2 diabetes mellitus as
described, for example, by the UK Prospective Diabetes
M. Shimoda:Y. Kanda: S. Hamamoto: K. Tawaramoto:
M. Hashiramoto: M. Matsuki: K. Kaku (*)
Division of Diabetes, Endocrinology and Metabolism,
Department of Internal Medicine, Kawasaki Medical School,
577 Matsushima, Kurashiki,
Okayama 701-0192, Japan
e-mail: kka@med.kawasaki-m.ac.jp
Diabetologia (2011) 54:1098–1108
DOI 10.1007/s00125-011-2069-9Study [1]. To prevent diabetic complications, maintenance
of strict glycaemic control is necessary, but this requires
preservation of beta cell function. On the other hand,
human diabetic patients exhibit an early defect in glucose-
stimulated insulin secretion (GSIS) [2] and autopsy studies
have demonstrated reduced beta cell mass in diabetic
patients [3]. Thus, development of treatment strategies has
focused on ways to improve beta cell function and to
prevent beta cell death. Hence, there is increased interest in
determining whether newer drugs such as insulin-
sensitising agents produce sustained improvements in beta
cell function [4, 5]. Likewise, agents associated with
glucagon-like peptide-1 (GLP-1) have also attracted con-
siderable attention because they may alter the natural
history of type 2 diabetes by preserving pancreatic beta
cell mass [6–8] and function [9–11].
GLP-1 has several beneficial effects that counteract the
pathophysiology of diabetes mellitus. First, GLP-1 is a
potent glucose-lowering polypeptide that induces glucose-
dependent insulin secretion [12, 13] while suppressing
glucagon secretion [14, 15]. Second, GLP-1 has extra-
pancreatic effects, such as delayed gastric emptying [16,
17], appetite suppression [18] and improved insulin sensi-
tivity [19]. Third and last, GLP-1 stimulates beta cell
replication [20, 21], neogenesis [22] and differentiation
[22], as well as inhibiting beta cell apoptosis via reduction
of cellular stress [23–26]. Consequently, GLP-1-related
agents are currently regarded as a powerful treatment option
for type 2 diabetes [27, 28]. Liraglutide, a novel long-acting
GLP-1 derivative, is resistant to dipeptidyl peptidase-IV. Its
prolonged effects result from the substitution of Lys for
Arg34 and the addition of a glutamic acid and a 16C NEFA
to the Lys26 residue of native GLP-1 [29].
To investigate the molecular mechanism by which
liraglutide preserves pancreatic beta cell mass, we treated
obese diabetic db/db mice with liraglutide for 2 days or
2 weeks. We also treated normoglycaemic m/m mice with
liraglutide for 2 weeks.
Methods
Animals Male 9-week-old BKS.Cg-+ Lepr
db/+ Lepr
db/Jcl
(db/db) mice and BKS. Cg-m+/m+/Jcl (m/m) mice were
purchased (Clea, Tokyo, Japan). They were housed two to
three animals per cage in all experiments under controlled
ambient conditions and a 14:10 h light/dark cycle with
lights on at 07:00 hours. Animals were given free access to
drinking water and conventional food (Oriental Yeast,
Tokyo, Japan). They received a subcutaneous injection of
liraglutide (200 μg/kg) or vehicle (PBS) twice daily (09:00
and 16:00 hours). Doses of the peptides used in the study
were based on a review of the literature [7]. Body weight
and food intake were monitored weekly from 9 weeks of age.
All experiments were approved by the Kawasaki Medical
School Animal Experiment Committee (No. 06-062) and
were performed in accordance with the Kawasaki Medical
School guidelines for animal experiments.
Measurement of biochemical markers Blood samples were
collected from the tail veinonce per week. Blood glucose was
measured immediately using a commercially available
enzyme electrode method (FreeStyle; Kissei Pharmaceutical,
Nagano, Japan). Plasma was separated and stored at −80°C
until use. The concentration of insulin in the plasma was
measured using an ELISA kit (Morinaga Institute of
Biological Science, Yokohama, Japan) and the plasma
triacylglycerol concentration was determined enzymatically
(E-Test; Wako, Osaka, Japan).
Insulin tolerance test After the 2 day or 2 week liraglutide
treatment in db/db mice, an insulin tolerance test was
performed by a intraperitoneal injection of insulin (2 units/kg
body weight) after an overnight fast. Blood samples were
collected from the tail vein every 30 min and blood glucose
was determined immediately as described above.
Measurement of insulin content in pancreatic islets Pancre-
atic islets were isolatedusingthe collagenase digestionmethod
as previously described [30]. Briefly, Hanks’ balanced salt
solution containing 1.5 mg/ml collagenase (Collagenase P;
Roche, Basel, Switzerland) and 10% (vol./vol.) fetal calf
serum was infused into the bile duct. The excised pancreas
was transferred to Hanks’ balanced salt solution and
centrifuged three times for 2 min each time at 1,100 rpm
(200 g). The final pellet was passed through a metal filter and
the filtrate was centrifuged for 22 min at 2,500 rpm (1,000 g)
using Histopaque-1077 (Sigma, St Louis, MO, USA). The
islet samples were stored at −80°C until measurement of
insulin content.
Measurement of triacylglycerol content in pancreatic
islets Pancreatic islets were isolated as described above and
45–60 of the isolated pancreatic islets were washed twice in
PBS, to which 50 μl of a high-salt buffer (2 mol/l NaCl,
2 mmol/l EDTA, 50 mmol/l sodium phosphate) was added,
followed by sonication for 1 min to disrupt the pancreatic
islets.Aftercentrifugationfor5minat12,000rpm(13,000g),
10 μl of the supernatant fraction was mixed with 10 μl
t-butanol plus 50 μl Triton X-100-methyl alcohol (1:1).
Triacylglycerol content in the pancreatic islets was measured
using E-Test (Wako) according to the manufacturer’s
instructions.
Glucose-stimulated insulin secretion from isolated pancreatic
islets Size-matched pancreatic islets were prepared (five
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buffer containing 5 mg/ml BSA, pH 7.4, and 95% O2/5%
CO2 saturated at 37°C for 60 min. The supernatant fraction
was replaced with a 3.0 or 16.7 mmol/l glucose solution,
and the mixture was incubated for an additional 60 min.
The supernatant fraction was recovered and stored at −80°C
until the insulin assay was performed.
Immunohistochemistry Pancreas tissue sections (4 μm)
were stained with haematoxylin–eosin. For immunostain-
ing, the sections were immersed for 15 min in methanol
containing 3% (vol./vol.) hydrogen peroxide to block
endogenous peroxidase activity. After rinsing with PBS
(10 mmol/l, pH 7.0), the sections were incubated for 1 h
with a mixture of antibodies (rabbit anti-glucagon antibody:
anti-somatostatin antibody 1:1; Nichirei, Tokyo, Japan) at
25°C. Tissue sections were also incubated for 14 h at 4°C
with either a mouse anti-insulin monoclonal antibody, an
anti-proliferative cell nuclear antigen (PCNA) monoclonal
antibody (Nichirei) or a mouse anti-4-hydroxy-2-noneal
modified protein (4HNE) monoclonal antibody (25 μg/ml;
Japan Institute for the Control of Aging, Shizuoka, Japan).
After rinsing with PBS, simple stain diaminobenzidine
solution (Nichirei) was added and the mixture was
incubated for 7 min at 25°C. The sections were counter-
stained with haematoxylin. To investigate cell apoptosis, a
TUNEL assay was performed using a colorimetric apopto-
tic detection system (DeadEnd; Promega, Madison, WI,
USA), as described previously [31].
Morphometric analysis The image analysis software NIH
Image (Version 1.61; http://rsbweb.nih.gov/ij/) was used to
calculate the entire pancreatic area, islet area and glucagon-
and somatostatin-positive cells, and also to determine the
relative islet area and the relative beta cell area. Using 15
sections (i.e. five sections from three different areas of the
pancreas) for each group of mice, beta cell mass was
estimated by the following formula: beta cell mass (mg)=
the pancreas weight (mg)×per cent pancreatic islet area×
percent beta cell count.
Laser capture microdissection According to our previously
established procedure [32], frozen, 8 μm thick tissue slices
were immediately stained and subjected to laser capture
microdissection. After tissue staining, the islets were
irradiated with a laser using the PixCell system (Arcturus,
Mountain View, CA, USA). The peripheral area was first
removed and then the beta-cell-rich core area was collected.
Real-time PCR RNA was extracted using an RNA isolation
kit (PicoPure PN 12206-01; Arcturus). TaqMan reverse
transcription reagents (N808-0234; Applied Biosystems,
Foster, CA, USA) were used for reverse transcription and
random hexamers were used as primers for cDNA
synthesis. The primers were designed using Primer Express
(Applied Biosystems) and were based on mRNA sequences
downloaded from the GenBank nucleotide database
(www.ncbi.nlm.nih.gov/nuccore).
A reaction solution was prepared by combining 0.5 μlo f
the sample, 1 μl of a 50 nmol/l primer solution, 5 μl Sybr
Green PCR Master Mix (Applied Biosystems) solution and
3.5 μl diluent. Dissociation curve analysis was performed
for each experiment to determine the dissociation temper-
ature and the size of the PCR products was confirmed by
agarose gel electrophoresis. We examined gene expression
in the core area of the pancreatic islets, selecting primary
genes for which a statistically significant difference
between the groups in the first gene expression experiment
had been observed. The genes analysed in the present study
were those associated with cell differentiation (Hlxb-9 [also
known as Mnx1], Hes1, Neurod [also known as Neurod1]
and Pdx1), cell proliferation (CycD and Erk-1 [also known
as Mapk3]), endoplasmic reticulum (ER) stress (Xbp1),
antioxidative stress (Cat and Gpx), lipid synthesis (Srebp-1c
[also known as Srebf1] and Fas) and cell apoptosis (Bcl2,
Casp8, Casp3 and Cad). To quantify gene expression, 2ΔCt
was calculated using 18S rRNA as an internal control.
Statistical analysis All data are presented as means ± SEM.
A Mann–Whitney U test was used to test for differences
among multiple groups, with p<0.05 regarded as signifi-
cant. The statistical analyses were performed with StatView
(version 5; SAS, Cary, NC, USA).
Results
Metabolic variables in db/db mice with chronic liraglutide
treatment After 1 week of treatment, liraglutide significantly
decreased food intake (23.7±1.6 vs 39.8±0.8 g per week,
p<0.0001; Fig. 1a) and suppressed body weight gain
(41.3±0.4 vs 43.3±0.5 g, p<0.05; Fig. 1b)i ndb/db mice
compared with vehicle-treated mice. Liraglutide also
reduced fasting glucose (7.0±0.4 vs 9.4±0.6 mmol/l,
p<0.05; Fig. 1c) and insulin concentrations (567.9±51.6
vs 1,032±86.1 pmol/l, p<0.01; Fig. 1d)i ndb/db mice after
1 week of treatment. These effects were sustained by
prolonged intervention with liraglutide until 2 weeks, at
which time the liraglutide-treated group had a significant
improvement in hypertriacylglycerolaemia (1.3±0.03 vs
1.5±0.07 mmol/l, p<0.01; Fig. 1e). We also found that
brief liraglutide treatment, i.e. for 2 days, resulted in similar
metabolic improvements (Fig. 2a, b, d). The exception was
fasting insulin, which was increased by 2 days of liraglutide
treatment compared with vehicle (826.1±86.1 vs 567.9±
34.4 pmol/l, p<0.05; Fig. 2c). Insulin sensitivity in db/db
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treatment (Figs 1f, 2e).
Islet function and morphology in db/db mice treated with
liraglutide To investigate whether 2 weeks of liraglutide
treatment exerted beneficial effects on the pancreatic islets
of db/db mice, we first subjected isolated pancreatic islets
to morphological analysis and immunostaining with anti-
bodies against glucagon and somatostatin. While liraglutide
treatment in db/db mice conserved the normal morphology
of pancreatic islets, in which glucagon- and somatostatin-
positive cells were observed in the periphery, vehicle
treatment disrupted these structures (Fig. 3a). In addition,
beta cell mass was significantly increased in liraglutide-
treated db/db mice, compared with vehicle-treated mice
(7.7±0.7 vs 4.9±0.5 mg, p<0.01; Fig. 3b).
After the 2 week intervention, islet insulin content in
liraglutide-treated db/db mice was greater than that in db/db
mice treated with vehicle for 2 weeks (33.7±2.3 vs 17.2±
2.1 ng/islet, p<0.01; Fig. 3i). Although islet insulin content
in vehicle-treated db/db mice tended to decrease with age
(2 days 24.7±2.7 vs 2 weeks 17.2±2.1 ng/islet, p=0.1;
Fig. 3i), that in mice treated with liraglutide for 2 weeks
was increased compared with mice treated with liraglutide
for 2 days (2 weeks 33.7±2.3 vs 2 days 27.0±1.7 ng/islet,
p<0.05; Fig. 3i).
After 2 weeks of liraglutide treatment, insulin secretion
was increased in response to 16.7 mmol/l glucose, but not
Fig. 1 Metabolic variables in
diabetic db/db mice treated for
2 weeks with vehicle
(diamonds) or liraglutide
(squares). a Food intake, (b)
body weight, (c) Fasting blood
glucose, (d) fasting plasma
insulin concentration,
(e) fasting plasma
triacylglycerol concentration
and (f) insulin sensitivity
assessed by an i.p. insulin
tolerance test. Results of the
insulin tolerance test are
expressed as a percentage
relative to the basal blood
glucose concentration before
insulin administration. n=7
for each group; *p<0.05,
**p<0.01, ***p<0.001;
†p<0.005
Fig. 2 Metabolic variables in
diabetic db/db mice treated for
2 days with vehicle (black bar,
diamonds) or liraglutide (white
bar, black squares). a Body
weight (BW) change, (b) fasting
blood glucose, (c) fasting plas-
ma insulin concentration, (d)
fasting plasma triacylglycerol
concentration and (e) insulin
sensitivity assessed by i.p.
insulin tolerance test. Results of
the tolerance test are expressed
as a percentage relative to the
basal blood glucose concentra-
tion before insulin administra-
tion. n=11 for each group;
*p<0.05, ***p<0.001
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Fig. 3k). However, 2 days of liraglutide treatment had no
effect on insulin secretion, irrespective of glucose concen-
tration (Fig. 3k). These results suggest that chronic
liraglutide treatment improved the reactivity of pancreatic
beta cells in response to the higher glucose concentration.
Next, we examined the effect of liraglutide treatment on
islet triacylglycerol content, which was not affected by
2 days of liraglutide treatment (Fig. 3j), although hyper-
triacylglycerolaemia was improved (Fig. 2d). However, the
accumulation of triacylglycerol in the pancreatic islets was
prevented by 2 weeks of liraglutide treatment (Fig. 3j),
despite an increase in islet triacylglycerol content with
ageing in vehicle-treated mice.
A morphological examination was used to study the
mechanisms involved in the restoration of pancreatic beta
cell mass by liraglutide in db/db mice. Histological sections
of the pancreatic islet were stained by an antibody specific
Fig. 3 Islet morphology and function in db/db mice treated with
vehicle (black bars) or liraglutide (white bars) for 2 days or 2 weeks. a
Haematoxylin–eosin staining, followed by double immunohistochem-
ical staining with antibodies against glucagon and somatostatin. Scale
bars 100 μm. b Beta cell mass, measured as described; n=5 (a, b). c
Immunohistochemical staining with antibodies against PCNA, quan-
tified (d) as ratio. e, f 4-HNE and (g, h) TUNEL assays and
quantification as indicated. c–h n=3 for each assay, scale bars
100 μm. The proportion of cells positive for PCNA (c, d) and
4-HNE (e, f) was measured in each islet and expressed as average
proportion for a minimum of 50 islets from each experimental animal.
DNase-treated cells were used as a positive control in the TUNEL
assay (g, h), with results of the TUNEL assay expressed as the
average number of TUNEL-positive cells per islet by assessing a
minimum of 50 islets from each experimental animal. i Islet insulin
content and (j) islet triacylglycerol content; n=5.k GSIS was assessed
by use of lower and higher glucose concentrations (3 mmol/l and
16.7 mmol/l); n=5. *p<0.05, **p<0.01
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measured to evaluate the proliferative effect on pancreatic
islets. Liraglutide-treated mice exhibited a significant
increase in PCNA-positive cells in pancreatic islets
(Fig. 3c, d). Oxidative stress, which was evaluated by
scoring 4-HNE-positive cells in pancreatic islets, was
reduced in the pancreatic islets of liraglutide-treated mice
(Fig. 3e, f), while cellular apoptosis, analysed by a TUNEL
assay, was suppressed (Fig. 3g, h).
Effect of liraglutide on gene expression in pancreatic beta
cells of db/db mice Both 2 weeks and 2 days of liraglutide
treatment significantly augmented expression of genes
involved in cellular differentiation (Hlxb-9, Neurod and
Pdx1; Fig. 4a, c, d, g, i, j) and significantly reduced
expression of an anti-differentiation gene (Hes1) in pancre-
atic beta cells of db/db mice (Fig. 4b, h). The expression of
genes involved in cellular proliferation (CycD and Erk-1)
was also increased significantly in db/db mice treated with
liraglutide for 2 weeks, with similar results obtained in mice
treated for 2 days (Fig. 4e, f, k, l). Liraglutide also
significantly increased expression of the anti-apoptotic
Bcl2 gene (Fig. 4m, q) and reduced expression of pro-
apoptotic genes (Casp8, Casp3 and Cad) in both treatment
regimens (Fig. 4n, o, p, r, s, t).
In contrast, chronic but not acute liraglutide treatment
significantly increased the expression of genes involved in
anti-oxidative stress (Cat and Gpx; Fig. 4u, v, z, aa) and
significantly reduced those related to ER stress (Xbp1;
Fig. 4w, bb) and lipid synthesis (Srebp-1c and Fas) in beta
cells of db/db mice (Fig. 4x, y, cc, dd). The expression
profile of Srebp-1c and Fas (Fig. 4x, y, cc, dd), which was
consistent with islet triacylglycerol content (Fig. 3j), indi-
cated that liraglutide alleviates the lipotoxicity experienced
by beta cells in a time-dependent fashion. Together, these
results suggest that liraglutide directly accelerates cellular
differentiation and proliferation, and inhibits apoptosis via a
reduction in oxidative and ER stress mediated by improve-
ments in glucolipotoxicity.
Impact of liraglutide on metabolism in normoglycaemic
mice We next investigated the effect of liraglutide in normo-
glycaemic m/m mice, which were treated with or without
liraglutide for 1 week. Food intake in m/m mice, compared
with the vehicle-treated group, was significantly reduced by
liraglutide treatment (21.1±0.8 vs 27.9±1.0 g/week, p<0.05;
Fig. 5a), as was body weight gain (20.1±0.2 vs 22.2±0.9 g,
p<0.05; Fig. 5b). These effects were sustained by prolonged
liraglutide treatment for up to 2 weeks, but were not
correlated with metabolic variables, such as fasting concen-
trations of blood glucose, insulin and triacylglycerol, which
did not differ statistically between liraglutide-treated and
vehicle-treated m/m mice (Fig. 5c–e).
Effect of liraglutide on morphology, function and gene
expression of pancreatic beta cells in normoglycaemic
mice In m/m mice, beta cell mass and islet insulin content
were significantly increased by liraglutide treatment (1.0±
0.1 vs 0.7±0.1 mg, p<0.01; 59.0±3.7 vs 44.4±3.9 ng/islet,
p<0.05; Fig. 6a, b). The increases in beta cell mass and islet
insulin content were associated with improvements in GSIS
in isolated islets in response to 16.7 mmol/l glucose (1.6±0.1
vs 1.2±0.03 ng/ml per islet, p<0.05; Fig. 6c) in the
liraglutide-treated group compared with the vehicle-treated
group.
The number of PCNA-positive cells was significantly
increased (Fig. 6d), suggesting that the proliferation of
pancreatic islets was upregulated in liraglutide-treated m/m
mice. Nevertheless, the numbers of 4-HNE-positive and
TUNEL-positive cells in the pancreatic islets did not differ
between liraglutide- and vehicle-treated m/m mice
(Fig. 6e, f). At the level of mRNA expression, m/m
mice treated with liraglutide for 2 weeks experienced a
significant increase in expression of genes involved in
cellular differentiation (Hlxb-9, Neurod and Pdx1; Fig. 7a,
c, d) and proliferation (Erk-1 and CycD; Fig. 7e, f), along
with a significant reduction in expression of an anti-
differentiation gene (Hes1; Fig. 7b). The expression of
mRNA for genes associated with cell apoptosis, anti-
oxidative stress, ER stress and lipid synthesis was not
statistically different between liraglutide- and vehicle-
treated mice (Fig. 7g–o). These results suggest that
liraglutide affects beta cell mass by stimulating cellular
differentiation and proliferation without affecting blood
glucose, insulin or triacylglycerol concentrations.
Discussion
In the present study, we investigated the effects of
liraglutide on obese diabetic mice. We found that the beta
cell mass of db/db mice was increased by long-term
liraglutide treatment. These results are essentially consistent
with previous reports describing a stimulatory effect on beta
cell mass of exendin-4, a potent GLP-1 receptor agonist, in
a partial pancreatectomy rat model of type 2 diabetes [20]
and of liraglutide, the long-acting GLP-1 derivative, in
diabetic db/db mice [7].
The present results demonstrate that short- and long-term
treatment with liraglutide affected mRNA expression of
Hlxb-9, Hes1 and Neurod in the core of islets in diabetic
db/db mice. The roles of several genes with well defined
functions in pancreatic development, such as those men-
tioned above (Hlxb9, Hes-1 and Neurod) have not been
previously studied in the adult pancreas. On the other hand,
previous studies have suggested that the Notch signal
through hairy and enhancer of split-1 (HES1) is activated
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regeneration, such as inflammation and neoplasia in the
pancreas [33, 34]. In addition, a recent in vitro study also
demonstrated that HES1 is involved in determining the beta
cell fate of adult human beta cells [35]. These findings
suggest the possibility that genes associated with an early
stage of endocrine pancreas development are expressed in
adult db/db mice and that liraglutide affects the expression
of those genes. However, the present results cannot be
regarded as conclusive, and further studies will be required
to elucidate this issue.
In this study, cell proliferation related to CycD and Erk-1
gene expression was readily upregulated in diabetic and
normoglycaemic mice treated with liraglutide for 2 days.
Immunohistochemical analysis of the pancreatic islets
suggested that enhancement of cellular proliferation might
be an underlying mechanism that accounts for the restor-
ative effects of GLP-1 on pancreatic beta cell mass. These
Fig. 4 Gene expression in the core area of islets in db/db mice treated
with vehicle (black bars) or liraglutide (white bars). a–f Expression of
genes involved in cell differentiation and proliferation after 2 weeks
and (g–l) 2 days of treatment. a, g Hlxb-9,( b, h) Hes1,( c, i) Neurod,
(d, j) Pdx1,( e, k) Erk1,( f, l) CycD. m–t Expression of genes involved
in pro-apoptosis and anti-apoptosis after 2 weeks (m–p) and 2 days
(q–t) of treatment. m, q Bcl2,( n, r) Casp8,( o, s) Casp3,( p, t) Cad.
u–dd Expression of genes involved in anti-oxidative stress, ER stress
and lipid synthesis after 2 weeks (u–y) and 2 days (z–dd) of treatment.
u, z Gpx,( v, aa) Cat,( w, bb) Xbp1,( x, cc) Fas,( y, dd) Srebp-1c. n=4
for each group; *p<0.05, **p<0.01;
†p<0.005;
‡p<0.0001;
§p=0.08
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affects pancreatic beta cell mass by directly stimulating
cellular proliferation. Interestingly, a previous study dem-
onstrated that pancreatic beta cell mass in non-diabetic rats
was significantly increased after 1 week of liraglutide
treatment, but no different from that in control animals after
6 weeks of treatment, indicative of a temporary effect on
beta cell mass [36]. This result suggests that the effect of
liraglutide on beta cell kinetics is acute and temporary in
non-diabetic conditions.
The binding of GLP-1 to its receptors activates adenylate
cyclase and the cyclic AMP/protein kinase A signalling
pathway. Additionally, GLP-1 activates phosphoinositide 3-
kinase (PI3K), p42 mitogen-activated protein kinase
(MAPK) and the epidermal growth factor receptor [37–39].
Furthermore, activation of the transcription factor for Pdx1
[38], p38 MAPK and protein kinase C-zeta [40]r e p o r t e d l y
plays a role in GLP-1-induced DNA synthesis and replica-
tion. Thus there is emergent evidence for extensive cross-talk
between the G-protein-coupled receptor and tyrosine kinase-
coupled receptor signalling pathways in beta cells. The
results of the present study show that modulation of the
CycD gene is involved in the liraglutide-induced increase in
beta cell mass, presumably through the MAPK pathway. We
alsofoundthatcellulardifferentiationisaffectedbyliraglutide
via upregulation ofPdx1, which is located downstream of the
PI3K–protein kinase B–forkhead box O1 pathway.
Liraglutide modified the expression of genes related to
cell apoptosis such as Bcl2, Casp8, Casp3 and Cad in db/db
mice during short- and long-term treatment, whereas mRNA
levels of these genes were not altered in normoglycaemic
m/m mice, suggesting that liraglutide directly suppressed
Fig. 5 Metabolic variables in
normoglycaemic m/m mice trea-
ted with vehicle (diamonds) or
liraglutide (squares). a Food
intake, (b) body weight, (c)
fasting blood glucose, (d) fast-
ing plasma insulin concentration
and (e) fasting plasma triacyl-
glycerol concentration. n=5 for
each group; *p<0.05, **p<0.01
Fig. 6 Islet morphology and
islet function in m/m mice trea-
ted for 2 weeks with vehicle
(black bars) or liraglutide (white
bars). a Pancreatic beta cell
mass, (b) islet insulin content
and (c) GSIS. d Immunohisto-
chemical staining of the pancre-
atic islet with antibodies against
PCNA, (e) 4-HNE and (f)
TUNEL. n=4 for each group;
*p<0.05, **p<0.01
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In a previous report, extracellular signal-regulated kinase
(ERK)1/2 regulated Bcl2 gene expression and protein
production, as well as the activity of caspase 3 through the
regulation of cyclic AMP-responsive element-binding pro-
tein [41]. Furthermore, the extracellular matrix directly
suppressed caspase 8 activity through regulation of the
ERK but not the PI3K pathway in pancreatic beta cells [42].
These results indicate that liraglutide may have a direct anti-
apoptotic effect, which is at least partly mediated by ERK.
With regard to the effect of GLP-1 on oxidative stress,
Tews and co-workers [26] reported that exendin-4 directly
reduces oxidative stress through counterregulation of the
reduced abundance of electron transport chain proteins in
INS-1 beta cells. In the present study, immunohistological
analysis with anti-4-HNE staining and the TUNEL assay
showed that 2 weeks of liraglutide treatment inhibited
cellular oxidative stress and apoptosis of the pancreatic islets
in diabetic db/db mice. We also showed that 2 weeks, but not
2 days of liraglutide treatment suppressed expression of Cat
and Gpx. The expression of Srebp-1c and Fas mRNAs, as
well as islet triacylglycerol content were also decreased only
by the 2 week liraglutide treatment regimen. These results
suggest that, in contrast to the action of exendin-4 in cultured
cell lines, the improvements in oxidative stress observed
with liraglutide treatment in db/db mice are secondary to
improvements in glucolipotoxicity.
The inhibitory effect of long-term liraglutide treatment
on expression of Xbp1 in the core area of pancreatic islets,
which should reflect a decrease in the unfolded protein
accumulated in the ER of pancreatic beta cells, is
essentially consistent with the findings of Yusta et al.,
who reported that chronic administration of exendin-4
decreased expression of Chop (also known as Ddit3) and
spliced Xbp1 in the pancreatic islets of db/db mice [43].
They also found that exendin-4 potentiated the induction of
activating transcription factor 4, a transcription factor
mediated by phosphorylated eukaryotic translation initia-
tion factor 2 α (eIF2α), in the INS-1 beta cell in a manner
that is dependent on protein kinase A, accelerating recovery
from ER stress-mediated translational repression by growth
arrestand DNA-damage-inducible34, which promoteseIF2α
dephosphorylation [43]. Contrary to the in vitro findings
reported by Yusta et al. [43], the present in vivo study
demonstrated that even short-term liraglutide treatment did
not affect expression of Xbp1 in hyperglycaemic mice. The
different study conditions, in vivo and in vitro experiments,
may have led to these different results.
Fehmann and Habener demonstrated a stimulatory effect
of GLP-1 on proinsulin biosynthesis in insulinoma beta
TC-1 cells [9]. In the present study, we found that
liraglutide enhanced the responsiveness of beta cells to
a glucose challenge in diabetic and normoglycaemic
mice. These results are essentially consistent with
previous studies that have reported an improved respon-
siveness of the pancreatic beta cells to glucose when
isolated mouse islets were incubated with liraglutide
[10].
Fig. 7 Gene expression in the core area of islets in m/m mice treated
with vehicle (black bars) or liraglutide (white bars) for 2 weeks. a–f
Expression of genes involved in cell differentiation and proliferation,
i.e. (a) Hlxb-9,( b) Hes1,( c) Neurod,( d) Pdx1,( e) Erk1 and (f) CycD.
g–j Expression of genes involved in cell apoptosis, i.e. (g) Bcl2,( h)
Casp8,( i) Casp3 and (j) Cad. k–o Expression of genes involved in
anti-oxidative stress, ER stress and lipid synthesis, i.e. (k) Gpx,( l)
Cat,( m) Xbp1,( n) Fas and (o) Srebp-1c. n=4 for each group;
*p<0.05;
†p<0.005
1106 Diabetologia (2011) 54:1098–1108In conclusion, we have demonstrated that liraglutide
restores pancreatic beta cell mass due to acute effects on
cell kinetics and chronic effects on oxidative and ER stress
that are secondary to improvements in glucolipotoxicity.
These conclusions were mainly obtained by analysing the
changes of gene expression in pancreatic islet cells. To fully
understand the effect of liraglutide on pancreatic beta cell
mass, further investigations, e.g. assessing the effect of
liraglutide on peptide expression and function, as well as its
role in neogenesis from the ducts, should be conducted.
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